Head-To-Head Survey: Eyegate Pharmaceuticals (EYEG) & Apricus Biosciences (APRI)

Eyegate Pharmaceuticals (NASDAQ: EYEG) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.


This table compares Eyegate Pharmaceuticals and Apricus Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eyegate Pharmaceuticals -1,737.29% -840.69% -105.23%
Apricus Biosciences -128.02% N/A -91.93%

Valuation & Earnings

This table compares Eyegate Pharmaceuticals and Apricus Biosciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Eyegate Pharmaceuticals $767,481.00 25.11 -$13.31 million ($1.30) -0.86
Apricus Biosciences $5.76 million 3.66 -$10.05 million $0.68 2.43

Apricus Biosciences has higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eyegate Pharmaceuticals has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Eyegate Pharmaceuticals and Apricus Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eyegate Pharmaceuticals 0 0 4 0 3.00
Apricus Biosciences 0 0 2 0 3.00

Eyegate Pharmaceuticals currently has a consensus price target of $7.33, suggesting a potential upside of 554.76%. Apricus Biosciences has a consensus price target of $4.50, suggesting a potential upside of 172.73%. Given Eyegate Pharmaceuticals’ higher possible upside, equities analysts plainly believe Eyegate Pharmaceuticals is more favorable than Apricus Biosciences.

Institutional & Insider Ownership

13.0% of Eyegate Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.3% of Apricus Biosciences shares are owned by institutional investors. 24.6% of Eyegate Pharmaceuticals shares are owned by insiders. Comparatively, 3.6% of Apricus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Apricus Biosciences beats Eyegate Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply